Literature DB >> 2731978

Optimal induction of tumor necrosis factor production in human monocytes requires complete S-form lipopolysaccharide.

D N Männel1, W Falk.   

Abstract

Optimal activation of human monocytes in vitro for the biosynthesis of tumor necrosis factor was achieved only with complete S-form lipopolysaccharide. Endotoxin preparations with shorter carbohydrate chains or the lipid A component of lipopolysaccharide were not able to induce release of comparable amounts of tumor necrosis factor by monocytes under the conditions described. The same differences in the level of tumor necrosis factor mRNA were observed. Moreover, addition of these agents to appropriate monocyte-activating substances inhibited the production of tumor necrosis factor. The regulatory implications of this phenomenon are discussed.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2731978      PMCID: PMC313826          DOI: 10.1128/iai.57.7.1953-1958.1989

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  UV crosslinking of RNA to nylon membrane enhances hybridization signals.

Authors:  E W Khandjian
Journal:  Mol Biol Rep       Date:  1986       Impact factor: 2.316

2.  Trace levels of bacterial lipopolysaccharide prevent interferon-gamma or tumor necrosis factor-alpha from enhancing mouse peritoneal macrophage respiratory burst capacity.

Authors:  A H Ding; C F Nathan
Journal:  J Immunol       Date:  1987-09-15       Impact factor: 5.422

3.  A reproducible microanalytical method for the detection of specific RNA sequences by dot-blot hybridization.

Authors:  S Cheley; R Anderson
Journal:  Anal Biochem       Date:  1984-02       Impact factor: 3.365

4.  Tumor necrosis factor production by human sarcoid alveolar macrophages.

Authors:  P R Bachwich; J P Lynch; J Larrick; M Spengler; S L Kunkel
Journal:  Am J Pathol       Date:  1986-12       Impact factor: 4.307

5.  Molecular requirement for interleukin 1 induction by lipopolysaccharide-stimulated human monocytes: involvement of the heptosyl-2-keto-3-deoxyoctulosonate region.

Authors:  S Lebbar; J M Cavaillon; M Caroff; A Ledur; H Brade; R Sarfati; N Haeffner-Cavaillon
Journal:  Eur J Immunol       Date:  1986-01       Impact factor: 5.532

6.  Protection of mice against lethal endotoxemia by a lipid A precursor.

Authors:  R A Proctor; J A Will; K E Burhop; C R Raetz
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

7.  Induction of human interleukin 1 by bacterial and synthetic lipid A.

Authors:  H Loppnow; L Brade; H Brade; E T Rietschel; S Kusumoto; T Shiba; H D Flad
Journal:  Eur J Immunol       Date:  1986-10       Impact factor: 5.532

8.  Role of lipid A in the production of tumor necrosis factor and differences in antitumor activity between tumor necrosis factor and lipopolysaccharide.

Authors:  K Haranaka; N Satomi; A Sakurai; O Kunii
Journal:  Tohoku J Exp Med       Date:  1984-12       Impact factor: 1.848

9.  Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance.

Authors:  B Beutler; N Krochin; I W Milsark; C Luedke; A Cerami
Journal:  Science       Date:  1986-05-23       Impact factor: 47.728

10.  IFN-gamma-induced production of monocyte cytotoxic factor.

Authors:  O Kildahl-Andersen; T Espevik; J Nissen-Meyer
Journal:  Cell Immunol       Date:  1985-10-15       Impact factor: 4.868

View more
  12 in total

Review 1.  Bacterial modulins: a novel class of virulence factors which cause host tissue pathology by inducing cytokine synthesis.

Authors:  B Henderson; S Poole; M Wilson
Journal:  Microbiol Rev       Date:  1996-06

2.  Adaptation to bacterial lipopolysaccharide controls lipopolysaccharide-induced tumor necrosis factor production in rabbit macrophages.

Authors:  J C Mathison; G D Virca; E Wolfson; P S Tobias; K Glaser; R J Ulevitch
Journal:  J Clin Invest       Date:  1990-04       Impact factor: 14.808

3.  IgA against gut-derived endotoxins: does it contribute to suppression of hepatic inflammation in alcohol-induced liver disease?

Authors:  Alexandr Parlesak; Christian Schäfer; Christiane Bode
Journal:  Dig Dis Sci       Date:  2002-04       Impact factor: 3.199

4.  Opposing effects of interferon-gamma on iNOS and interleukin-10 expression in lipopolysaccharide- and mycobacterial lipoarabinomannan-stimulated macrophages.

Authors:  T I Roach; C H Barton; D Chatterjee; F Y Liew; J M Blackwell
Journal:  Immunology       Date:  1995-05       Impact factor: 7.397

5.  Regulation of murine macrophage effector functions by lipoarabinomannan from mycobacterial strains with different degrees of virulence.

Authors:  L B Adams; Y Fukutomi; J L Krahenbuhl
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

6.  Parvoviruses are inefficient in inducing interferon-beta, tumor necrosis factor-alpha, or interleukin-6 in mammalian cells.

Authors:  J R Schlehofer; M Rentrop; D N Männel
Journal:  Med Microbiol Immunol       Date:  1992       Impact factor: 3.402

7.  Isoniazid protects mice against endotoxin lethality without influencing tumor necrosis factor synthesis and release.

Authors:  R Urbaschek; D N Männel; R Urbanczik
Journal:  Antimicrob Agents Chemother       Date:  1991-08       Impact factor: 5.191

8.  Differential induction of tumor necrosis factor by bacteria expressing rough and smooth lipopolysaccharide phenotypes.

Authors:  N M Kelly; L Young; A S Cross
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

9.  Similar mechanisms of action of defined polysaccharides and lipopolysaccharides: characterization of binding and tumor necrosis factor alpha induction.

Authors:  M Otterlei; A Sundan; G Skjåk-Braek; L Ryan; O Smidsrød; T Espevik
Journal:  Infect Immun       Date:  1993-05       Impact factor: 3.441

10.  In vitro expansion and analysis of T lymphocyte microcultures obtained from the vaccination sites of cancer patients undergoing active specific immunization with autologous Newcastle-disease-virus-modified tumour cells.

Authors:  M Stoeck; C Marland-Noske; M Manasterski; R Zawatzky; S Horn; V Möbus; P Schlag; V Schirrmacher
Journal:  Cancer Immunol Immunother       Date:  1993-09       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.